HCW Biologics (HCWB) Competitors $4.18 +0.01 (+0.24%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$4.18 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock HCWB vs. KALA, ALXO, ENLV, GBIO, TPST, DARE, SNYR, CARA, PASG, and CVKDShould you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include KALA BIO (KALA), ALX Oncology (ALXO), Enlivex Therapeutics (ENLV), Generation Bio (GBIO), Tempest Therapeutics (TPST), Dare Bioscience (DARE), Synergy CHC (SNYR), Cara Therapeutics (CARA), Passage Bio (PASG), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. HCW Biologics vs. Its Competitors KALA BIO ALX Oncology Enlivex Therapeutics Generation Bio Tempest Therapeutics Dare Bioscience Synergy CHC Cara Therapeutics Passage Bio Cadrenal Therapeutics KALA BIO (NASDAQ:KALA) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Does the media favor KALA or HCWB? In the previous week, HCW Biologics had 1 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for HCW Biologics and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.63 beat HCW Biologics' score of 0.27 indicating that KALA BIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HCW Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate KALA or HCWB? KALA BIO currently has a consensus price target of $13.50, indicating a potential upside of 155.20%. HCW Biologics has a consensus price target of $35.00, indicating a potential upside of 737.32%. Given HCW Biologics' higher possible upside, analysts clearly believe HCW Biologics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in KALA or HCWB? 24.6% of KALA BIO shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 8.3% of KALA BIO shares are owned by company insiders. Comparatively, 42.7% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, KALA or HCWB? KALA BIO has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Is KALA or HCWB more profitable? KALA BIO has a net margin of 0.00% compared to HCW Biologics' net margin of -1,712.94%. HCW Biologics' return on equity of 0.00% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets KALA BION/A -369.29% -64.99% HCW Biologics -1,712.94%N/A -90.09% Which has preferable valuation and earnings, KALA or HCWB? HCW Biologics has lower revenue, but higher earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKALA BIO$3.89M8.77-$38.51M-$8.24-0.64HCW Biologics$2.57M2.34-$30.02M-$23.25-0.18 SummaryKALA BIO beats HCW Biologics on 8 of the 15 factors compared between the two stocks. Get HCW Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCWB vs. The Competition Export to ExcelMetricHCW BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.84M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-0.1821.5627.5220.22Price / Sales2.34281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book-0.697.518.045.67Net Income-$30.02M-$55.05M$3.18B$249.13M7 Day Performance-7.11%4.61%2.90%3.28%1 Month Performance-29.75%4.72%3.70%5.55%1 Year Performance-83.18%5.92%36.15%21.12% HCW Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCWBHCW Biologics3.3412 of 5 stars$4.18+0.2%$35.00+737.3%-83.1%$5.84M$2.57M-0.1840KALAKALA BIO3.7795 of 5 stars$4.02-0.5%$13.50+235.8%-22.4%$26.07M$3.89M-0.4930ALXOALX Oncology2.6621 of 5 stars$0.46-5.0%$3.30+617.9%-91.6%$25.84MN/A-0.1940Positive NewsGap UpENLVEnlivex Therapeutics3.1892 of 5 stars$1.16+6.4%$10.00+762.1%-11.7%$25.78MN/A-1.7670Positive NewsGBIOGeneration Bio2.9795 of 5 stars$0.36-5.3%$7.33+1,937.6%-85.7%$25.47M$24.56M-0.33150TPSTTempest Therapeutics1.7935 of 5 stars$6.85+1.0%$30.00+338.0%-74.0%$24.97MN/A-0.3820DAREDare Bioscience1.7657 of 5 stars$2.56-9.2%$12.00+368.8%-22.3%$24.96M$10K-15.0630News CoverageGap DownHigh Trading VolumeSNYRSynergy CHC3.7606 of 5 stars$2.57-3.0%$10.00+289.1%N/A$24.36M$34.83M0.0040Gap UpCARACara Therapeutics0.3548 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumePASGPassage Bio3.079 of 5 stars$0.33-14.4%$7.50+2,140.1%-48.3%$24.30MN/A-0.33130Gap UpCVKDCadrenal Therapeutics3.042 of 5 stars$11.44-7.4%$32.00+179.7%N/A$24.29MN/A-1.244Gap Down Related Companies and Tools Related Companies KALA BIO Competitors ALX Oncology Competitors Enlivex Therapeutics Competitors Generation Bio Competitors Tempest Therapeutics Competitors Dare Bioscience Competitors Synergy CHC Competitors Cara Therapeutics Competitors Passage Bio Competitors Cadrenal Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCWB) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
